“… stretch scarce Federal resources as far as possible, reaching more eligible patients and providing more comprehensive services…”
We’ve all heard the tagline for the 340B program, but what does it mean? The PHSA of 1992 mandates pharmaceutical manufacturers that want to be included in the Medicare and Medicaid formularies to provide medications at substantially reduced pricing to entities that are considered eligible. HRSA has been designated the overseer and eligibility arm of this program yet leaves the policing to the pharmaceutical manufacturers.
…but regardless of the manufacturer, covered entity, HRSA or other third-party audits…the data remains consistently inconsistent. Manufacturers rely on the policing of pricing to exist with the distributors. Distributors rely on contract pharmacies. Contract pharmacies rely on Covered Entities.
Manufacturers rely on the Covered Entities to ensure that the discounts received on covered-eligible medication is appropriate and meets all the definitions of eligibility and participation. And despite HRSA suggested self-audit and vendor audit documents, covered entities can abuse and create vulnerabilities in their organization, for their c-suite and ultimately for the patients which they serve.
A fully transparent supply chain holds each party accountable for their actions and prevents fraud, waste and abuse. FWA is the mechanism that allows healthcare costs to rise.
PharmaSEE is the platform that brings clarity tothis hazy world. It allows for a “pill-to-patient” tracking, reporting and certification to ensure that every transaction meets the highest standard of care. Tracked through a continuous monitoring stream, we keep you compliant.
Fundamental reform of the 340B program requires a clear linkage between the patients who establish 340B eligibility and those who benefit from receipt of 340B-discounted drugs.
